Effect of Erythropoietin on Lymphocytes Apoptosis in Experimental Chronic Renal Failure

Abstract

Recombinant human erythropoietin was injected intraperitoneally in a total dose of 900 U/kg to rats with experimental chronic renal failure. Suspension of lymphocytes from animals with chronic renal failure was used in vitro, erythropoietin was used in concentrations of 30, 15, 7.5, 3.75, and 1.88 U/liter. Intact cells (Annexin-5-FITC(-)/7-AAD(-)), cells with early signs of apoptosis (Annexin-5-FITC(+)/7-AAD(-)), cells with late signs of apoptosis and partially necrotic cells (Annexin-5-FITC(+)/7-AAD(+)), as well as cells with early signs of necrosis (Annexin-5-FITC(-)/7-AAD(+)) were differentiated by fl ow cytometry. It was found that the number of peripheral blood lymphocytes with early and late signs of apoptosis and necrosis increased in chronic renal failure. Erythropoietin at a total dose of 900 U/kg reduced the number of blood lymphocytes with signs of apoptosis and necrosis and thus elevated the number of intact lymphocytes. Erythropoietin in concentrations ranging from 1.88 to 30.0 U/liter dose dependently lowered the number of lymphocytes with early signs of apoptosis and the number of lymphocytes with the signs of late apoptosis and necrosis in vitro.

Intranasal administration of erythropoietin rescues the photoreceptors in degenerative retina: a noninvasive method to deliver drugs to the eye

“…EPO is initially recognized as a glycoprotein to stimulate the generation of erythrocytes. Accumulating evidence shows that EPO also governs the development, differentiation, and survival of neural cells by modulating apoptotic pathways (Osikov et al., 2015). Pioneering studies have translated the EPO induced favorable effects into clinical utility.…”

Neuroprotective Effect of Erythropoietin at Experimental Spinal Cord Ischemia

“…Результаты многочисленных клинических и экспериментальных исследований свидетельствуют об эффектах ЭПО на функциональное состояние сердечнососудистой системы, нервной системы, аффективный статус, систему гемостаза, иммунный статус, репродуктивную систему и почки [3, 10, 12-14, 23, 24]. Ранее нами установлено позитивное влияние ЭПО на аффективный статус, психофизиологический статус, функциональное состояние вегетативной нервной системы у больных хронической почечной недостаточностью, реализуемое за счет антианемического и дезинтоксикационного действия ЭПО [7][8][9][10][11][12][13]. Показано, что плейотропные эффекты ЭПО реализуются за счет наличия к нему специфических рецепторов на различных клетках, в том числе на нейронах [25].…”